Here's How GMED Is Capitalizing on the Musculoskeletal Market Boom
According to a report by Market Research Intellect, the musculoskeletal system market was valued at $15.6 billion in 2025 and is projected to witness a CAGR of 11.96% from 2026 to 2033, reaching an estimated $38.52 billion by 2033. This creates a favorable setup for Globus Medical’s GMED broad implant portfolio across spine and orthopedics.
In the first quarter of 2026, worldwide net sales rose 27% year over year, while base business sales, excluding Nevro, increased 13.2%.
U.S. Spine marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anterior lumbar interbody fusion, posterior cervical and cervical plating. International Spine grew 16.4% as reported in the first quarter.
Trauma revenues increased 30.4% in the quarter, aided by continued adoption of the core trauma line and the Precice limb lengthening portfolio, with ANTHEM Elbow continuing to exceed expectations, prompting the company to ship additional sets to the field in the second quarter.
Peer Update
Zimmer BiometZBH continues to see stable demand across the global musculoskeletal market, supported by procedure volumes and ongoing new product adoption. While pricing remains a key swing factor, the first-quarter 2026 performance suggests end markets have remained resilient.
In the first quarter, large joints sales remained positive. Hips net sales were up 3.2% organically and total Knees net sales increased 1.8% organically. International net sales grew 4.2% at constant currency and 2.5% organically, reflecting healthy demand trends despite varying performance across countries.
Stryker’s SYK long-term growth potential is underpinned by a vast and expanding total addressable market across its Orthopaedics business. Mako remains central to Stryker’s orthopaedics strategy and supports recurring pull-through from implants, consumables, and service.
In the first quarter of 2026, the company reported a record first-quarter performance for Mako installations in both the United States and international markets, supported by high and rising utilization rates. Management also highlighted positive surgeon feedback for Mako Shoulder and expects a full launch of Mako 4 in mid-2026. The launch is anticipated to broaden the range of procedures performed on the platform and further support utilization growth.
GMED’s Stock Price Performance
Over the past year, GMED shares have surged 33.5%, outperforming the industry’s 6.0% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month Price-to-Sales (P/S) of 3.30X compared with the industry median of 4.76X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).
